STOCK TITAN

Bristol-Myers Squibb Co. (BMY) Stock News

BMY NYSE

Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.

Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.

Rhea-AI Summary

Bristol Myers Squibb (BMY) plans to present new data on blood cancers and rare blood disorders at the 2026 American Society of Hematology meeting.

The meeting runs December 12–15 in New Orleans, with more than 90 company- and partner-sponsored disclosures, including 24 oral presentations. The lineup includes Phase 3 results for ZENBEXUS and mezigdomide combinations in relapsed or refractory multiple myeloma, plus Phase 1 data on the cell therapies tunlucabtagene autoleucel and arlocabtagene autoleucel.

Bristol Myers Squibb sees potential for a cure with Breyanzi in second-line relapsed or refractory large B-cell lymphoma based on five-year Phase 3 TRANSFORM follow-up. The meeting will also feature Phase 2 results for golcadomide plus rituximab in newly diagnosed advanced follicular lymphoma and Reblozyl data in alpha- and beta-thalassemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb (BMY) reported its first preliminary Phase 3 results for KarXT in patients with psychosis associated with Alzheimer’s disease. Both studies reported lower hallucination and delusion scores from the start of open-label treatment, when participants knew they were receiving KarXT.

In the 12-week ADEPT-1 lead-in, the mean hallucination and delusion score fell 12.0 points from 14.4. In the 52-week ADEPT-3 extension, it fell 5.1 points from 8.9. Mean overall severity scores fell 1.9 points from 4.5 in ADEPT-1 and 0.8 points from 3.4 in ADEPT-3.

No new safety signals were identified. Serious adverse events arising during treatment occurred in 5.0% of ADEPT-1 participants and 7.7% of ADEPT-3 participants. The findings are descriptive, and the ADEPT trials are ongoing and double-blind data remain blinded.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) will unify research and development under Cristian Massacesi, effective January 1, 2027. Massacesi, currently executive vice president and chief medical officer, will lead the combined organization, bringing scientific and clinical expertise together from discovery through development.

Chief research officer Robert Plenge will remain in an advisory capacity through March 2027 before departing. Plenge and Massacesi developed the new structure together. The company aims to use the combined organization to advance its pipeline faster and improve portfolio execution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) presented 56-week Phase 3 results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, a heart condition. SCOUT-HCM enrolled 44 patients aged 12 to <18 years; 43 completed the 28-week placebo-controlled period and then received Camzyos through week 56.

Patients receiving Camzyos throughout had a mean 48.1 mmHg reduction from baseline in Valsalva left ventricular outflow tract gradient, a measure of blood-flow obstruction. The placebo group showed a similar reduction after switching. No patient had left ventricular ejection fraction, a measure of pumping function, below 50%, and no new safety signals were reported. Treatment-related adverse events and serious treatment-emergent events numbered five and two in the continuous-treatment arm. The FDA approved Camzyos in September 2026 for symptomatic patients weighing at least 30 kg.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
Rhea-AI Summary

Viz.ai announced that two studies evaluating its AI-based electrocardiogram technology were accepted for presentation at an HCMS meeting. The meeting is held alongside the American Heart Association’s Scientific Sessions 2026 in Chicago. Both studies examine Viz HCM, which helps identify suspected hypertrophic cardiomyopathy, a heart muscle disease.

University of Colorado researchers analyzed ECGs from more than 29,000 patients; nearly 40% of patients flagged for suspected HCM had no corresponding diagnosis code. A Beth Israel Deaconess study found detection beyond standard ECG measurements, with flagged patients having a 2.68-fold higher hazard of adverse clinical events. Viz HCM was developed under a multi-year agreement with Bristol Myers Squibb (NYSE: BMY).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
AI
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) reported third quarter 2026 financial results and posted detailed earnings materials on its Investor Relations website. Executives will review the results during a conference call and live webcast at 8:00 a.m. ET on October 29, 2026. A replay will be available approximately three hours after the call concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
Rhea-AI Summary

Bristol Myers Squibb (BMY) announced Phase 3 results showing iza-bren improved progression-free survival versus chemotherapy in previously treated EGFR-mutated lung cancer.

The PANKU-Lung01 interim analysis studied patients with non-squamous non-small cell lung cancer previously treated with an EGFR tyrosine kinase inhibitor. Median progression-free survival, the primary endpoint measuring time without disease worsening, was 11.1 months versus 5.7 months with platinum-based chemotherapy (hazard ratio 0.40; p<0.0001). Confirmed response rates were 60.2% versus 34.5%, and median response duration was 10.4 versus 5.7 months. Overall survival data remained immature, with a favorable trend. Treatment-related adverse events caused 1.9% to discontinue iza-bren; two patients had adjudicated interstitial lung disease. Iza-bren has FDA Breakthrough Therapy Designation for previously treated advanced EGFR-mutated disease and is jointly developed outside China with SystImmune.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) presented interim Phase 1 Breakfree-2 results for zola-cel in patients with multiple sclerosis. The single-arm study included 66 patients with highly active relapsing or progressive disease; safety was the primary endpoint.

All 60 patients at dose level 2 remained off disease-modifying therapies at last follow-up, including nine followed for more than 12 months. Among evaluable patients at ≥ Week 26, six of seven with relapsing disease met no-evidence-of-disease-activity criteria; 22 of 24 with progressive disease had stable or improved disability, and all 24 had no new MRI activity.

Cytokine release syndrome occurred in 42.4%, and immune-related neurological toxicity in 7.6%, including one Grade 4 event that resolved. After data cutoff, one patient died from septic pneumonia 44 days after infusion, following unresolved motor symptoms and high-dose cyclophosphamide treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
-
Rhea-AI Summary

Pathos AI announced multi-year collaborations with Bristol Myers Squibb (BMY) and Tempus AI (TEM) to advance drug development for neurological conditions.

Tempus will build a de-identified dataset tracking outcomes over time for hundreds of thousands of patients with neurological conditions. Pathos will license it under a five-year, $55 million agreement and apply its Foundry AI platform to study disease biology and inform clinical-trial design, beginning with Alzheimer’s disease and other neurological conditions.

Bristol Myers Squibb leads Pathos’s Series E financing and gains multi-year, non-exclusive access to Foundry across its broader research and development portfolio, plus three-year exclusive rights to support neuroscience development programs. Bristol Myers Squibb aims to use the platform and dataset to better understand disease progression and design more precise trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
partnership AI
Rhea-AI Summary

Tempus AI (TEM) signed a multi-year agreement for Bristol Myers Squibb (BMY) to license its oncology data through 2031. The agreement covers de-identified data combining multiple types of information to support biological and clinical insights, drug target discovery and therapeutic development across BMS’s oncology portfolio.

BMS will also gain access to Tempus’ Lens Platform, where researchers can train and run AI models using de-identified data and dedicated computing infrastructure. The agreement expands an existing relationship involving AI and real-world data for clinical trial design in oncology and neuroscience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
partnership

FAQ

What is the current stock price of Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb (BMY) last closed at $58.80.

What is the market cap of Bristol-Myers Squibb (BMY)?

The market cap of Bristol-Myers Squibb (BMY) is approximately $120.2B.